Variability in non‐nucleoside reverse transcriptase and protease inhibitors concentrations among HIV‐infected adults in routine clinical practice
- 12 January 2007
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 63 (6) , 715-721
Abstract
The objective of this study was to assess interindividual variability in plasma trough concentrations of non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI) among HIV-infected adults in an outpatient routine clinical practice setting. The study included 117 patients who attended our clinic for routine outpatient blood tests and who were receiving antiretroviral therapy which included NNRTI or PI. Patients were not informed that drug concentrations were going to be assessed until blood sampling. The time of the last antiretroviral treatment intake and blood sampling were recorded. Drug concentrations were considered optimal if they were above the proposed minimum effective concentration. In addition, efavirenz, nevirapine and atazanavir concentrations were considered potentially toxic if they were higher than 4.0 mg l(-1), 6.0 mg l(-1), and 0.85 mg l(-1), respectively. Overall, interindividual variability in NNRTI and PI plasma concentrations was approximately 50%, and only 68.4% of the patients had drug concentrations within the proposed therapeutic range. Inappropriate adherence only explained 35% of subtherapeutic drug concentrations. Interindividual variability in trough concentrations of NNRTI and PI among HIV-infected adults is large in routine clinical practice, with drug concentrations being outside the therapeutic window in a significant proportion of patients. Therapeutic drug monitoring may be useful to guide antiretroviral therapy in clinical practice.Keywords
This publication has 27 references indexed in Scilit:
- Predictors of HIV Drug‐Resistance Mutations in a Large Antiretroviral‐Naive Cohort Initiating Triple Antiretroviral TherapyThe Journal of Infectious Diseases, 2005
- Lopinavir Plasma Levels in Salvage Regimes by a Population of Highly Active Antiretroviral Therapy-Treated HIV-1–Positive PatientsAIDS Patient Care and STDs, 2004
- Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individualsAIDS, 2003
- High Variability of Plasma Drug Concentrations in Dual Protease Inhibitor RegimensAntimicrobial Agents and Chemotherapy, 2003
- Human Immunodeficiency Virus Type 1 Genotypic and Pharmacokinetic Determinants of the Virological Response to Lopinavir-Ritonavir-Containing Therapy in Protease Inhibitor-Experienced PatientsAntimicrobial Agents and Chemotherapy, 2002
- Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detectionJournal of Chromatography B: Biomedical Sciences and Applications, 2001
- Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral DosingAntimicrobial Agents and Chemotherapy, 2001
- Relationships Between Exposure to Saquinavir Monotherapy and Antiviral Response in HIV-Positive PatientsClinical Pharmacokinetics, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997